SCHEMBL21486469

SCHEMBL21486469

CCn1cc(C2CC2)ccc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.41
KDM4A O75164 1/20 0.38
KDM4B O94953 1/20 0.38
KDM5C P41229 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
PDE10A Q9Y233 1/20 0.37
SLC6A4 P31645 1/20 0.36
CREBBP Q92793 1/20 0.35
BRD4 O60885 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
ACSS2 Q9NR19 1/20 0.35
DPP4 P27487 1/20 0.34
DPP7 Q9UHL4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL629163 0.90 ESR2 (0.46) DRD2KDM4AKDM4BKDM5CKDM5B
SCHEMBL12975680 0.89 HTR2C (0.42) DRD2KDM4AKDM4BKDM5CKDM5B
SCHEMBL629063 0.82 EBP (0.36) DRD2KDM4AKDM4BKDM5CKDM5B
SCHEMBL21475938 0.75 QDPR (0.38) DRD2CREBBPBRD4
SCHEMBL628249 0.73 ESR2 (0.42) PDE10AHRH3
SCHEMBL12575366 0.72 MAPT (0.43) CREBBPMEN1ALDH1A1LMNATSHR
SCHEMBL27973341 0.71 ESR2 (0.36) DRD2BRD4
SCHEMBL24022882 0.70 CASP3 (0.38) HRH3
SCHEMBL627753 0.70 ESR2 (0.44) PDE10AHRH3
SCHEMBL629194 0.70 ESR2 (0.47) DRD2HRH3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11174228-B2 Antagonists of human integrin (α4)(β7) MORPHIC THERAPEUTIC, INC. (US) 2021-11-16 US disclosed
US-20200385352-A1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) MORPHIC THERAPEUTIC, INC. 2020-12-10 US disclosed
US-10759756-B2 Antagonists of human integrin α4β7 MORPHIC THERAPEUTIC, INC. (US) 2020-09-01 US disclosed
US-20190315692-A1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) MORPHIC THERAPEUTIC, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315692-A1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) ITGB7, ITGB4, ITGA4 DRD2 2407/4885KDM4A 2022/4885KDM4B 1609/4885
US-11174228-B2 Antagonists of human integrin (α4)(β7) ITGB7, ITGB4, ITGA4 DRD2 2889/4885KDM4A 2786/4885KDM4B 2133/4885
US-20200385352-A1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) ITGB7, ITGB4, ITGA4 DRD2 2407/4885KDM4A 2022/4885KDM4B 1609/4885
US-10759756-B2 Antagonists of human integrin α4β7 ITGB7, ITGB4, ITGA4 DRD2 3659/4885KDM4A 2603/4885KDM4B 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.